$BNGO

BioNano Genomics, Inc

CIK:0001411690|SEC Filings

Unaudited Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue:
Total revenue	$ 8,171	$ 6,733	$ 14,858	$ 13,190
Cost of revenue:
Total cost of revenue	3,857	3,256	7,292	6,774
Operating expenses:
Research and development	2,988	2,931	6,127	5,299
Selling, general and administrative	8,544	8,346	16,554	17,379
Total operating expenses	11,532	11,277	22,681	22,678
Loss from operations	(7,218)	(7,800)	(15,115)	(16,262)
Other income (expense):
Interest income	146	277	369	566
Other income (expense)	(344)	676	(963)	5,756
Total other income (expense)	(198)	953	(594)	6,322
Loss before income taxes	(7,416)	(6,847)	(15,709)	(9,940)
Provision for income taxes	(7)	(10)	(17)	(18)
Net loss	$ (7,423)	$ (6,857)	$ (15,726)	$ (9,958)
Net loss per share, basic (in dollars per share)	$ (0.64)	$ (1.99)	$ (1.4)	$ (3.24)
Weighted-average common shares outstanding, basic (in shares)	11,546	3,441	11,264	3,070
Net loss per share, diluted (in dollars per share)	$ (0.64)	$ (1.99)	$ (1.4)	$ (3.24)
Weighted-average common shares outstanding, diluted (in shares)	11,546	3,441	11,264	3,070
Product revenue
Revenue:
Total revenue	$ 7,693	$ 6,310	$ 13,787	$ 12,314
Cost of revenue:
Total cost of revenue	3,724	3,150	6,929	6,202
Service and other revenue
Revenue:
Total revenue	478	423	1,071	876
Cost of revenue:
Total cost of revenue	$ 133	$ 106	$ 363	$ 572

Unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities:
Net Income (Loss)	$ (15,726)	$ (9,958)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	4,606	4,814
Amortization of financing lease right-of-use asset	102	102
Accretion of interest on securities	(303)	(491)
Non-cash lease expense	114	582
Gain on lease termination/modification	0	(450)
Stock-based compensation	1,640	2,667
Cost of leased equipment sold to customer	146	215
Change in fair value of convertible debentures	287	(5,250)
Disposal of property and equipment	34	258
Changes in operating assets and liabilities
Accounts receivable	834	1,257
Inventory	(29)	1,834
Prepaid expenses and other current assets	313	45
Other long-term assets	591	666
Accounts payable	(1,028)	(719)
Accrued expenses, contract liabilities, and lease liabilities, net	(1,967)	(1,823)
Net cash used in operating activities	(10,386)	(6,251)
Investing activities:
Purchase of available for sale securities	(80,131)	(116,642)
Sale and maturities of available for sale securities	99,269	104,555
Net cash provided by (used in) investing activities	19,138	(12,087)
Financing activities:
Principal payments of financing lease liability	(41)	(34)
Proceeds from sale of common stock and warrants	1,325	16,408
Offering expenses on sale of common stock and warrants	(54)	(1,023)
Proceeds from warrant and option exercises	0	9
Payments on convertible debentures	(10,266)	(3,000)
Net cash provided by (used in) financing activities	(9,036)	12,360
Effect of exchange rates on cash and cash equivalents and restricted cash	6	(33)
Net increase (decrease) in cash and cash equivalents and restricted cash	(278)	(6,011)
Cash and cash equivalents and restricted cash at beginning of period	4,509	9,573
Cash and cash equivalents and restricted cash at end of period	4,231	3,562
Reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts reported on the condensed consolidated statements of cash flows
Cash and cash equivalents	3,730	3,562
Restricted cash	501	0
Total cash and cash equivalents and restricted cash at end of period	4,231	3,562
Supplemental disclosure of cash flow information
Cash paid for interest	600	921
Cash paid for operating lease liabilities	341	1,348
Supplemental disclosure of non-cash financing and investing activity
Transfer of instruments and servers from inventory into property and equipment, net	275	654
Issuance of common stock for convertible debentures payable	0	350
Fees paid in common stock	0	1,584
Operating lease liabilities resulting from obtaining right-of-use assets	$ 0	$ 2,966

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 3,730	$ 2,990
Investments	6,189	16,279
Accounts receivable, net	4,366	5,200
Inventory	5,202	5,448
Prepaid expenses and other current assets	4,890	5,203
Restricted cash and investments	501	10,266
Total current assets	24,878	45,386
Property and equipment, net	13,017	14,847
Operating lease right-of-use assets	2,935	3,217
Finance lease right-of-use assets	2,993	3,095
Intangible assets, net	1,665	4,345
Other long-term assets	2,103	2,694
Total assets	47,591	73,584
Current liabilities:
Accounts payable	4,562	5,590
Accrued expenses	3,456	5,460
Contract liabilities	1,145	967
Operating lease liability	633	697
Finance lease liability	243	249
Convertible debentures payable (at fair value)	0	9,979
Total current liabilities	10,039	22,942
Operating lease liability, net of current portion	2,384	2,489
Finance lease liability, net of current portion	3,444	3,480
Long-term contract liabilities	118	249
Total liabilities	15,985	29,160
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of June 30, 2026 and December 31, 2025	0	0
Common stock, $0.0001 par value; 400,000,000 shares authorized at June 30, 2026 and December 31, 2025; 11,777,300 and 10,740,200 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	1	1
Additional paid-in capital	766,937	764,026
Accumulated deficit	(735,346)	(719,620)
Accumulated other comprehensive income	14	17
Total stockholders’ equity	31,606	44,424
Total liabilities and stockholders’ equity	$ 47,591	$ 73,584